Qube Research & Technologies LTD An2 Therapeutics, Inc. Call Options Transaction History
Qube Research & Technologies LTD
- $91.4 Billion
- Q3 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ANTX
# of Institutions
35Shares Held
7.56MCall Options Held
0Put Options Held
0-
Almitas Capital LLC Santa Monica, CA1.43MShares$1.63 Million0.88% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.08MShares$1.23 Million0.0% of portfolio
-
Peapod Lane Capital LLC Bedford Hills, NY589KShares$671,7060.67% of portfolio
-
Stonepine Capital Management, LLC Bend, OR564KShares$642,8600.58% of portfolio
-
Bank Of Nova Scotia459KShares$523,4810.0% of portfolio
About AN2 Therapeutics, Inc.
- Ticker ANTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 19,402,700
- Market Cap $22.1M
- Description
- AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...